ArticleBiomolecules2026
Altered Iron Metabolism in Dogs with Naturally Occurring Cardiac Disease.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac disease represents a major cause of morbidity and mortality in dogs. In human cardiology, iron deficiency is a highly prevalent and clinically relevant comorbidity, contributing to exercise intolerance, symptom burden, and impaired quality of life independently of anemia, while correction with intravenous iron improves function and reduces hospitalization. Iron metabolism in dogs remains poorly characterized and typically considered only in the context of anemia. This study investigated iron metabolism and its regulatory pathways in dogs with cardiac disease, assessing whether alterations in iron handling and availability consistent with an iron-restricted phenotype are present. Hematologic indices, serum iron, total and unsaturated iron-binding capacity (TIBC, UIBC), ferritin, hepcidin, ceruloplasmin, C-reactive protein, and albumin were evaluated in 61 dogs comprising healthy controls, and dogs either with compensated cardiac disease (CCD group) or presenting acute decompensated congestive heart failure (ADCHF group). Dogs with cardiac disease exhibited evidence of systemic inflammation, reduced hematocrit, increased red blood cell distribution width, and decreased circulating iron. Both cardiac groups showed reduced TIBC and UIBC, suggesting decreased transferrin availability and reduced iron transport capacity, whereas ferritin concentrations did not differ between groups. Hepcidin concentrations were lower in CCD and not increased in ADCHF patients, suggesting complex and non-uniform regulation of iron homeostasis rather than a classic hepcidin-driven inflammatory pattern. In dogs with ADCHF, iron-binding capacity was independently associated with indices of cardiac remodeling, and additional correlation between inflammatory markers and iron-related parameters supported an interaction between inflammation, iron handling, and disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.